ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed … – Yahoo Finance
Chaffey Breeze |
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR–T Cell Therapy Targeting Relapsed …
Yahoo Finance “In vivo preclinical animal studies have demonstrated that these CAR–T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls, and I look forward to evaluating … Ziopharm Oncology: Key To The CAR–T Mint |
